1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: MK1-192, NCT00180128
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 0 to 75
Sponsor: Other
Protocol IDs: LPA 2005, NCT00408278
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LAP-R2007, NCT00504764
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 30052004, NCT00196768
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: LAL-AR/2003, NCT00853008
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: AML-01.10, NCT01587430
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: APL0406, GIMEMA-SAL-APL0406, EUDRACT-2006-006188-22, GIMEMA-DSL-APL0406, EU-20725, NCT00482833
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: BRD 06/10-I, NCT00860639
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057
|
|
10.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AAML1031, AAML1031, NCT01371981
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: OSHO#069, NCT01497002
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-306, NCT01522443
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1931022, NCT01564784
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 06U.70, 2005-74, NCT00410423
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 0603, NCT00414388
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000570266, MSKCC-05077, 05-077, NCT00546377
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 07-154, NCT00660036
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 10-0910 / 201106039, NCT00906945
|
|
19.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CAMN107YCA03T, NCT01222143
|
|
20.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: T2009-003, NCT01483690
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: CDR0000354225, UON-SHIELD, EU-20346, NCT00079105
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AMLSG-R1, NCT00744081
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: KC09MIMS0255, NCT01004497
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML22489, 2009-011433-27, NCT01144403
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TPLL2, 2008-001421-34, NCT01186640
|
Mobile | Español
